Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

https://www.cnbc.com/video/2020/04/03/past-outbreaks-history-pandemics-coronavirus-covid-19-squawk-b

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
condoe3 Member Profile
 
Followed By 1
Posts 666
Boards Moderated 0
Alias Born 02/02/12
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/27/2020 6:05:32 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/1/2020 4:53:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2020 4:16:53 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/25/2020 4:15:36 PM
Brainstorm Announces Grant of a New Japanese Patent for NurOwn® PR Newswire (US) - 9/16/2020 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2020 4:08:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:06:53 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/10/2020 6:07:14 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2020 7:01:27 AM
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update PR Newswire (US) - 8/5/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 5:11:22 PM
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update PR Newswire (US) - 7/27/2020 7:58:00 AM
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:16:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:10:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:05:43 PM
BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program PR Newswire (US) - 7/8/2020 5:31:00 AM
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS PR Newswire (US) - 7/2/2020 6:49:00 AM
BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar PR Newswire (US) - 7/1/2020 8:50:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/26/2020 5:02:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/26/2020 5:01:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/26/2020 5:01:04 PM
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease PR Newswire (US) - 6/24/2020 7:00:00 AM
BrainStorm Granted SME Status by the European Medicines Agency GlobeNewswire Inc. - 6/15/2020 9:00:10 AM
BrainStorm to Present at the Raymond James Human Health Innovations Conference PR Newswire (US) - 6/11/2020 7:28:00 AM
condoe3   Saturday, 08/15/20 09:13:31 AM
Re: None
Post # of 2834 
https://www.cnbc.com/video/2020/04/03/past-outbreaks-history-pandemics-coronavirus-covid-19-squawk-box.html

Richard Preston is out with a new book called “Crisis in the Red Zone: The Story of the Deadliest Ebola Outbreak in History, and of the Outbreaks to Come.” He joins “Squawk Box” to discuss the coronavirus outbreak as the U.S. tries to figure out where we are in the curve.

This was about as informative an interview on the subject of Covid19
he mentions the Bioreactor method for creating antibodies

In 2014 Brainstorm and Octane successfully constructed a Bioreactor

NEW YORK, NY and PETACH TIKVAH, ISRAEL and KINGSTON, ON--(Marketwired - June 27, 2014) - BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian firm that focuses on clinical systems for cell and tissue therapy, announced today that they have reached an important milestone in their technology collaboration, successfully constructing an Alpha prototype of a customized bioreactor for BrainStorm's NurOwn™ neurotrophic-factor secreting mesenchymal stem cells. The proprietary bioreactor under development will provide BrainStorm with large-scale manufacturing capabilities, enabling it to achieve economies of scale for its autologous stem cell product.

Octane and BrainStorm have successfully developed a sophisticated Alpha prototype of the NurOwn™ Bioreactor, utilizing a customized disposable cartridge that is dedicated to the intricacies of BrainStorm's NurOwn™ process. Operating within the Cocoon™ clinical delivery platform pioneered by Octane, the Alpha prototype automates the entire NurOwn™ process for unmatched process control and production economy. Based on this first working prototype, BrainStorm and Octane are quickly advancing to the next stage of system qualifications in anticipation of adopting all the benefits of cell production automation as quickly as possible for full clinical use

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences